To better understand whether anti‐amyloid treatments have a clinically meaningful benefit, we examined the relationships between the CDR‐SB and functional independence, an outcome important to patients and families. In a cohort of individuals diagnosed with early AD dementia who were confirmed to have amyloid pathology, we found that a loss of independence in IADLs occurs at CDR‐SB >4.5 and in BADLs occurs at CDR‐SB >11.5. We examined the rate of annual decline in CDR‐SB, and then estimated the time to loss of independence in IADLs (time until CDR‐SB = 4.5) and BADLs (time until CDR‐SB = 11.5). Finally, using published estimates quantifying the effects of anti‐amyloid treatments on slowing decline in the CDR‐SB, we estimated how long anti‐amyloid treatments are expected to extend independence in IADLs and BADLs.
